W. Rich

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis

N. Camp, A. Cox, G. Duff, 2005, Genes and Immunity.

Stem cell factor is a potent synergistic factor in hematopoiesis.

G. Demetri, J. Crawford, M. Gordon, 1994, Oncology.

Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial

D. Kuritzkes, D. Ward, R. Wong, 1998, AIDS.

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Stanley B. Cohen, J. Kremer, M. Weinblatt, 2002, Arthritis and rheumatism.

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.

J. Frazier, C. Edwards, A. Bendele, 2000, Arthritis and rheumatism.

Radioprotection of mice by recombinant rat stem cell factor.

K. Zsebo, K. Smith, I. Mcniece, 1992, Proceedings of the National Academy of Sciences of the United States of America.